scispace - formally typeset
Open AccessJournal Article

Cyclophosphamide regimens in rhesus monkey with and without marrow infusion.

Rainer Storb, +3 more
- 01 Aug 1970 - 
- Vol. 30, Iss: 8, pp 2195-2203
Reads0
Chats0
TLDR
Hematological and pathological effects of various high-dose regimens of cyclophosphamide (CY) were evaluated in rhesus monkeys and it was found that consistent allogeneic marrow grafts could be achieved after a nonlethal dose of 180 mg CY/kg administered over a 2-day period.
Abstract
Summary Hematological and pathological effects of various high-dose regimens of cyclophosphamide (CY) were evaluated in rhesus monkeys. An effort was made to find a dose range at which infusion of autologous marrow would prevent lethality. In addition, allogeneic marrow was transplanted following very large but nonlethal doses of CY. Twenty-five monkeys were given CY in doses of 100 to 240 mg/kg over 1- to 4-day periods. These doses of CY produced severe hemopoietic depression and generalized toxicity. Uneventful hemopoietic recovery and survival was the rule in monkeys given up to 200 mg/kg. After 240 mg/kg, most monkeys died, even when stored autologous marrow was infused, probably because of nonhemopoietic toxic effects of CY. Four groups of recipients (28 monkeys) were given nonlethal doses of CY followed by marrow infusion from donors of opposite sex. Criteria for allogeneic marrow engraftment were rising blood cell counts following the post-CY decline, occurrence of a lethal graft-versus-host disease, and the cytogenetic demonstration of marrow cells with donor karyotype. It was found that consistent allogeneic marrow grafts could be achieved after a nonlethal dose of 180 mg CY/kg administered over a 2-day period. Extending the total dose of CY over a 4-day instead of a 2-day period was less effective in preparing the host for acceptance of the marrow graft. After 150 mg CY/kg given over a 2-day or a 4-day period, permanent engraftment was not observed.

read more

Citations
More filters
Journal ArticleDOI

Technique for Human Marrow Grafting

TL;DR: A technique is described for marrow aspiration from living human donors and for processing the marrow for intravenous infusion to marrow graft recipients.
Journal ArticleDOI

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

TL;DR: Although the duration of PR is short as expected, CRs appear to be durable and CTCb is an intensification regimen with a low mortality that delivers a significantly increased dose of agents with known activity at conventional doses in breast cancer.
Journal ArticleDOI

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

TL;DR: It is indicated that a single treatment with intensive combination alkylating agents with bone marrow support can produce more rapid and frequent complete responses than conventional chemotherapy when used as initial chemotherapy for metastatic breast cancer, although median disease-free and overall survival is not improved.
Journal ArticleDOI

Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.

TL;DR: It is reaffirms the principle that drug toxicity correlates with dose per body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.
Journal ArticleDOI

Leukæmic transformation of engrafted human marrow cells in vivo

TL;DR: A 7-year-old girl with acute lymphoblastic leukaemia was given 1000 rad total-body irradiation followed by infusion of marrow from an HL-A matched brother, and prompt engraftment ensued, and, with methotrexate, significant graft-versus-host disease was not observed.
Related Papers (5)